We could not find any results for:
Make sure your spelling is correct or try broadening your search.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX... RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Show more
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...
- RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties...
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.1808 | 144.35207824 | 0.818 | 2.32 | 0.78925 | 36615092 | 1.73262175 | CS |
4 | 0.7588 | 61.1935483871 | 1.24 | 2.32 | 0.78925 | 8393620 | 1.71060396 | CS |
12 | -0.2312 | -10.3677130045 | 2.23 | 3.32 | 0.78925 | 3068092 | 1.71261474 | CS |
26 | -1.0812 | -35.1038961039 | 3.08 | 3.825 | 0.78925 | 1577618 | 1.81539987 | CS |
52 | -21.8212 | -91.6087321579 | 23.82 | 27.35 | 0.78925 | 1293689 | 4.83131019 | CS |
156 | -33.2712 | -94.3328607882 | 35.27 | 40.74 | 0.78925 | 668914 | 10.34133835 | CS |
260 | -28.8412 | -93.5188067445 | 30.84 | 51.2095 | 0.78925 | 521162 | 15.07014426 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions